On 27 Aug 2021, $Chembio Diagnostics(CEMI)$ announced its launch of commercial distribution of an FDA Emergency Use Authorized, patent pending, rapid point-of-care COVID-19 antigen test for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to Chembio customers across the United States with Institutions buying in with over 1 Million Shares reported purchased on Aug 30 2021.
This is Bullish! ??⚠️
$Atossa Genetics(ATOS)$$Bionano Genomics(BNGO)$$Quest Diagnostics(DGX)$$Theratechnologies Inc.(THTX)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- RahayuYunus·2021-09-08Patience and discipline is a virtue that will benefit all traders, keeping emotion and snap judgments in check.4Report
- SeahBW·2021-10-03time will tell this:)5Report
- Jaccvc78·2021-09-28nice4Report
- desjou·2021-09-10Be patient. Buy n hold. Pls like n share.2Report
- Akong·2021-10-04Too difficult to understand2Report
- RSXX·2021-09-26Ihg hi shxjdhdjhdichxkjd2Report
- 关耳火丙光军·2021-10-07good2Report
- gingergimo·2021-10-04nice2Report
- ppptt·2021-10-04?2Report
- tchaikovskia·2021-10-04Sweet nuts3Report
- Bullwings·2021-10-03Nice post2Report
- Aileen0225·2021-10-03good1Report
- V K·2021-09-30nice1Report
- JimmyLZH·2021-09-29??2Report
- Bobopo·2021-09-29Like2Report
- CKhinz·2021-09-28Wow4Report
- YG_TAN666·2021-09-26?3Report
- Jenny_Li·2021-09-24Good job3Report
- Milan83·2021-09-22Wow1Report
- Daron_Ooi·2021-09-22Nice1Report